Cytyc Gains Preterm Birth Diagnostic, Drug In $356 Mil. Adeza Acquisition

Cytyc is banking on its established women's health sales force to maximize the value of its $356 million purchase of Adeza Biomedical and its principal product Full Term, a diagnostic for preterm birth risk